PURPOSE: The authors report their 5-year experience with percutaneous transluminal angioplasty (PTA) for treatment of stenoses related to Takayasu arteritis. PATIENTS AND METHODS: Twenty patients were treated; 12 patients had renovascular hypertension at presentation, three patients had abdominal aortic coarctation syndrome, and five patients had aortoiliac occlusive disease. RESULTS: The initial success rate for patients with renovascular hypertension was 83%, with a 5-year patency of 33.3%. In patients with abdominal aortic coarctation, initial success rate was 100% but 5-year patency was 33.3%. In patients with aortoiliac occlusive disease, the initial success rate was 100%, with a 5-year patency of 60%. CONCLUSION: Despite the high initial success rate for PTA in these patients, the disease recurs in a substantial number of the, due to the fact that this technique does not treat the disease itself but only its consequences.
PURPOSE: The authors report their 5-year experience with percutaneous transluminal angioplasty (PTA) for treatment of stenoses related to Takayasu arteritis. PATIENTS AND METHODS: Twenty patients were treated; 12 patients had renovascular hypertension at presentation, three patients had abdominal aortic coarctation syndrome, and five patients had aortoiliac occlusive disease. RESULTS: The initial success rate for patients with renovascular hypertension was 83%, with a 5-year patency of 33.3%. In patients with abdominal aortic coarctation, initial success rate was 100% but 5-year patency was 33.3%. In patients with aortoiliac occlusive disease, the initial success rate was 100%, with a 5-year patency of 60%. CONCLUSION: Despite the high initial success rate for PTA in these patients, the disease recurs in a substantial number of the, due to the fact that this technique does not treat the disease itself but only its consequences.
Authors: Diego Porras; Deborah R Stein; Michael A Ferguson; Gulraiz Chaudry; Ahmad Alomari; Khashayar Vakili; Steven J Fishman; James E Lock; Heung B Kim Journal: Pediatr Nephrol Date: 2013-06-18 Impact factor: 3.714